UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/727,696	12/03/2003	Chaitan Khosla	300622000508	8649
	7590 09/23/200 FOERSTER LLP	EXAMINER		
12531 HIGH B	LUFF DRIVE	KIM, ALEXANDER D		
SUITE 100 SAN DIEGO, C	CA 92130-2040		ART UNIT	PAPER NUMBER
			1656	
			MAIL DATE	DELIVERY MODE
			09/23/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/727,696	KHOSLA ET AL.		
Examiner	Art Unit		
ALEXANDER D. KIM	1656		

	ALEXANDER D. KIM	1656	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress
THE REPLY FILED <u>08 September 2008</u> FAILS TO PLACE THIS	S APPLICATION IN CONDITION F	OR ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following rapplication in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:	eplies: (1) an amendment, affidavit al (with appeal fee) in compliance	t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expiresmonths from the mailing	date of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this Adno event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (l	ter than SIX MONTHS from the mailing	g date of the final rejection	n.
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).		
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extremely an extra transfer of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount of the corresponding a	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as
2. ☐ The Notice of Appeal was filed on A brief in compl	iance with 37 CFR 41 37 must be t	filed within two months	s of the date of
filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
AMENDMENTS			
 The proposed amendment(s) filed after a final rejection, be (a) They raise new issues that would require further core (b) They raise the issue of new matter (see NOTE below 	sideration and/or search (see NOT		cause
(c) They are not deemed to place the application in bett appeal; and/or	**	ducing or simplifying tl	ne issues for
(d) They present additional claims without canceling a converse NOTE: (See 37 CFR 1.116 and 41.33(a)).	orresponding number of finally reje	ected claims.	
4. The amendments are not in compliance with 37 CFR 1.12	1. See attached Notice of Non-Co	mnliant Amendment (PTOL-324)
5. Applicant's reply has overcome the following rejection(s):		inpliant / timenament (102 024).
Newly proposed or amended claim(s) would be all non-allowable claim(s).	·	imely filed amendmer	nt canceling the
7. For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1-5, 7, 10-13 and 31. Claim(s) withdrawn from consideration:		l be entered and an e	xplanation of
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 			
9. The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	ıl and/or appellant fail:	s to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attach	ed.
 The request for reconsideration has been considered but See Continuation Sheet. 	does NOT place the application in	condition for allowan	ce because:
12. ☐ Note the attached Information <i>Disclosure Statement</i>(s). (13. ☐ Other:	PTO/SB/08) Paper No(s)		
	/Chih-Min Kam/		
	Primary Examiner, Art U	nit 1656	

Continuation of 11. does NOT place the application in condition for allowance because: The request for reconsideration in the reply filed on 09/08/2008 has been considered, however, the amendment does not place the application in condition for allowance. The amendment to the claims filed on 09/08/2008 has been entered because the claims as amended does not raise new issues. However, in view of the entry of the amendment, applicant's arguments are not found persuasive to overcome the outstanding rejection(s) as set forth in the Office action mailed on 07/09/2008 for the reasons of record stated herein. Applicants argue that there is no case law addressing the issue of whether substituting "consists of" or "comprises" constitutes new matter and traverse since said amendment limits the claims only to those elements that is disclosed. However, the instant application does not disclose method having only two steps, i.e., excising a nucleotide sequence and ligating into a second nucleotide sequence, as if the novelty of instant invention is a method involving novel step of modifying DNA sequence(s). The instant application disclose, but not limited to, the method comprising at least steps of preparing a cosmid library of genomic DNA from Streptomyces hygroscopicus, excising and ligating a nucleotide sequence of interest to another nucleotide sequence, transforming into S. coelicolar using expression vector, manipulating macrolide ring size by mutagenesis using the expression system of Kao et al., wherein said step is different from method step as claimed in Claim 1 (Claims 2-5 and 31 dependent therefrom). Instant claimed invention having just two step of excising and ligating an AT domain to a second AT domain is not supported by the original disclosure. Thus, the previous new matter rejection under 35 USC 112 would be maintained. If Applicants argue that instant invention of having excising and ligating step within the application's disclosure supports the instant claim 1 by just looking at step of excising and ligating step, and not considering all the other step that is also recited in the original disclosure, then the previous rejecions under 35 USC 102 and 103 (which were withdrawn) would be a proper rejection by the same analogy that is just considering steps taught by Katz et al. disclosing steps consider to be excising and ligating nucleotide sequences. Furtheremore, Applicants also acknowledge that "Kao does teach such techniques" (see page 6, line 19, Remarks filed on 9/8/2008) would be considered for a prior art.

Applicants also traverse the previous 35 USC 103 rejection. Applicants argue that the previous remarks stating that Kao is irrelevant to these claims" clearly referes to claims 1-5 and 31, not to claims 7 and 10-13. The examiner acknowledge that the argument was made for traversal of Claims 1-5 and 31. Applicants also stated that applicants do not understand the recitation of page 6, lines 26-29 of the Katz PCT publication. However, as disclosed in the previous final rejection mailed on 7/9/2008, the recitation of page 6, lines 26-29 was referring to page of previous non-final rejection mailed on 10/26/2007).

Applicants acknowledge that claims 7 describe a variant of the method described by Kao as applied to exchanging an AT segment of a poyketide synthase-encoding sequence. However, the challenges in doing so are much greater because the flanking sequence that must be used to exchange just this segemnt must be matched in the donor and acceptor plasmids. Applicants argue that these regions are derived from different polyketide synthases and are assumned to be essential for the funciton of the synthases involved. However, method of instant claims is not limited to any specific and/or essential sequences as alleged by applicants. Thus, as previously noted, Claims 7 and 10-13 are unpatentable over by Katz (WO 93/13663) or U. S. P 5,824,513 ('513, IDS reference number 5) in view of the state of the art as exemplified by Kao et al. (IDS reference: Science 1994, 265, 509-512)..